Circulating Tumor DNA in Soft Tissue Sarcoma

This research study will collect blood and tumor tissue samples from patients with soft tissue sarcoma to look at circulating tumor deoxyribonucleic acid (DNA). When tumor cells are damaged or die, DNA from the tumor cells are released into the blood stream as the cells break down. This is called circulating tumor DNA. Circulating tumor DNA is an important biomarker that may be used in cancer detection, prediction of treatment response, and disease monitoring.

Trial Details

NCT ID
NCT03818412
Phase
NA
Sponsor
University Health Network, Toronto
Status
RECRUITING
Cancer Type
Sarcoma
Interventions
  • Archival tumor tissue collection and blood draws
Locations (sample)
  • Toronto, Ontario, Canada|43.65333,-79.38389

Key Eligibility Criteria

  • Patients must have histologically confirmed high-risk extremity or retroperitoneal liposarcoma, leiomyosarcoma and undifferentiated pleomorphic sar…
  • Patients must have archival tissue from the diagnostic biopsy available.
  • Deemed appropriate for preoperative or postoperative radiotherapy and curative surgery following patient assessment by radiation oncologist and sur…
  • Age 18 years or older.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Sarcoma Trials on Trialify →